spacer
home > epc > winter 2003 > which patient diary for which trial?
PUBLICATIONS
European Pharmaceutical Contractor

Which Patient Diary for Which Trial?

The process of developing and testing a new drug is lengthy, risky and costly. Various efforts are underway to reduce approval times and lower these risks. Technologies and processes that can help to ensure and accelerate FDA approval have the highest ROI impact for the sponsors. Among these efforts is the development and use of electronic patient diaries.

This article is not about patient compliance or how electronic patient diaries improve such compliance; these issues have already been documented extensively. Instead, we will focus on the factors to consider when choosing the best electronic patient diary for a trial.

ResearchandMarkets.com estimates that 25 to 30 per cent of all clinical trials currently use diaries, whether paper or electronic, to collect patient self-reported data (1). In 2002, the same report estimated that the proportion of patient diaries that use electronic format was approximately three per cent. It also forecasts that 25 per cent of patient diaries used in clinical trials will be electronic-based by 2007. As a vendor, we agree with this prediction based on changes we have seen in the industry.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Serge Bodart, CEO of Symfo (USA) Inc

Serge Bodart is the CEO at Symfo (USA) Inc. With over 20 years' experience in management, technology and quality processes, he successfully created the idea of the Symfo® Electronic Diary. Prior to joining Symfo, Serge was the CTO at EMC, a Belgian medical information technology company providing software and services to the pharmaceutical industry. He studied at the Royal Military Academy in Brussels, Polytechnic Division, and graduated with an Engineering degree in Telecommunications.

spacer
Serge Bodart
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Recommendations Sourcing Human Biospecimens

BioIVT

The foundations for protecting human research subjects come from the ethical principles surrounding the Belmont report : Respect for persons, beneficence, and justice. The use of human biospecimens in research supports these principles with legal and ethical regulations - the most important of which is permission.(1) This permission may come directly from the donor or granted by others with authorization to protect the interests of biospecimen donors.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement